Speeding Up in Premarket

Shoe Company Pops After Company's Hurdle Starts Disappearing‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Good morning Wake-Up Watchlisters! While you're sipping coffee you'll see US stocks inched higher on Wednesday. It's the second straight day of gains on Wall Street, with global bonds settling from yesterday's selloff. There was also some encouraging news from a major retail company (more on that below). There's been a lot of overvalued stocks in 2022, which begs the question 'what is a stock that could actually go UP in the future?' Our Head Fundamental Tactician Karim Rahemtulla believes this one company is dirt cheap, and could be in for one of the biggest bounce backs in 2023. Even more exciting - there's a shocking announcement in February that could send it soaring. Click here to reveal this $2 value stock. Here's a look at the top-moving stocks this morning. Nike (NYSE: NKE) Nike is up 12.23% premarket after its biggest problem may be vanishing. The shoe company is getting its inventory under control, which was caused by the economic pullback earlier this year. Inventory bloat hurt its profit margins, but now its down to just 3%, spurred by a high-single-digit percentage drop in units. Further progress is expected in the 2023 calendar year. We recently closed a trade on Nike in The War Room after BMO reiterated Nike as an outperform. These are the types of catalysts we look for and why we have a 77% win rate in 2022 despite some of the worst market conditions since 2008. Click here to unlock these winning trades. ADC Therapeutics (NYSE: ADCT) ADC Therapeutics is up 24.84% premarket after the European Commission announced the approval of ZYNLONTA™ for the treatment of relapsed or refractory diffuse large B-cell lymphoma. The major development follows positive opinions issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Major positive news like this in the medical sector can serve as a catalyst for major gains. Right now there's a medical device company that's still trading on bargain prices – but our friend Alexander Green calls it the 'Best Investment Opportunity in 37 years.' Click here to see why there's so much potential in this medical stock. The Greatest "Arbitrage" in History? One unique resource sells for just $10 in America... but $60-plus in Europe. In other words, you can buy it here... sell it there... and make six times your money! And now, one company is making $200 million per shipload doing exactly that. Here's why Wall Street analysts just upped their price projection for this company to $280 (it's about $30 today). Otonomy (Nasdaq: OTIC) Otonomy is down 9.52% premarket after the biotech company shut down its shop and laid off all its employees after a series of ear drug failures. The company intends to call a special meeting of its stockholders in the first quarter of 2023 to seek approval of the Plan of Dissolution. Applied UV (Nasdaq: AUVI) Applied UV, Inc. is down 8.19% premarket after the company announced two acquisitions, potentially doubling the size of the company. The disinfection technology solutions leader agreed to acquire privately held PURO Lighting LLC and LED Supply Co. The combined transaction value of these acquisitions would be approximately $20 million, including a combination of cash and restricted common and restricted preferred shares. If more economic pain persists in 2023, will you be prepared? Analysts currently project a 60% chance of a recession in 2023. Will you be ready for the worst? Gold and precious metal investing has been a proven way to combat inflation throughout history. And right now our friends at Stansberry Research are unveiling their 'No. 1 Gold Play for 2022.' It's not an ETF or Mining Stock. It's actually a virtually unknown investment, but it could pay you handsomely as gold soars higher. Click here to learn more about 'The No. 1 Gold Play for 2022.' Those are the top market movers today. Happy trading! The Wake-Up Watchlist Research Team Insiders Love This $30 Stock That Pays Out 10%+ Dividends Europe is suffering through a major energy crisis thanks to Russia shutting off gas supplies, but the company now delivering natural gas to Europe is making a fortune. PLUS... insiders now own 47% of this stock. Learn why Putin's mistake could drive this stock from $30 to $280 in 18 months! Monument Traders Alliance   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2022 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.